Sign Out
Hypersensitivity to the active substance or to any of the excipients listed in Description.
For patients with NSCLC, ramucirumab is contraindicated where there is tumour cavitation or tumour involvement of major vessels (see Precautions).
UserName
Profession Email
Profession Email
